New drug KAI-1678 tested for spinal cord injury pain
NCT ID NCT01135108
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tested whether KAI-1678, given as a single injection under the skin, can reduce pain in people with spinal cord injury. Only 5 adults with long-term spinal cord injury and chronic pain took part. The study compared KAI-1678 to a placebo to see if it improved pain scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KAI-1678
What this could lead to
If it works, this could point toward a new pain treatment for people with spinal cord injury.
What could go wrong
This is a very small, early Phase 2 trial with only 5 participants, so results may not apply broadly. The drug may not reduce pain better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sydney, New South Wales, Australia